Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors
Abstract Background and Aims Despite the revolutionary effects of hematopoietic stem cell transplantation (HSCT) in treating hematological malignancies, post‐HSCT relapse is considered a critical concern of clinicians. Residual malignant cells employ many mechanisms to evade immune surveillance and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-03-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.536 |
| _version_ | 1797224921487638528 |
|---|---|
| author | Elham Roshandel Farzaneh Tavakoli Sayeh Parkhideh Sedigheh Sadat Akhlaghi Maria Tavakoli Ardakani Masoud Soleimani |
| author_facet | Elham Roshandel Farzaneh Tavakoli Sayeh Parkhideh Sedigheh Sadat Akhlaghi Maria Tavakoli Ardakani Masoud Soleimani |
| author_sort | Elham Roshandel |
| collection | DOAJ |
| description | Abstract Background and Aims Despite the revolutionary effects of hematopoietic stem cell transplantation (HSCT) in treating hematological malignancies, post‐HSCT relapse is considered a critical concern of clinicians. Residual malignant cells employ many mechanisms to evade immune surveillance and survive to cause relapse after transplantation. One of the immune‐frustrating mechanisms through which malignant cells can compromise the antitumor effects is misusing the self‐limiting system of immune response by overexpressing inhibitory molecules to interact with the immune cells, leading them to so‐called “exhausted” and ineffective. Introduction of these molecules, known as immune checkpoints, and blocking them was a prodigious step to decrease the relapses. Methods Using keywords nivolumab, pembrolizumab, and ipilimumab, we investigated the literature to figure out the role of the immune checkpoints in the HSCT setting. Studies in which these agents were administrated for relapse after transplantation were reviewed. Factors such as the interval from the transplant to relapse, previous treatment history, adverse events, and the patients’ outcome were extracted. Results Here we provided a mini‐review discussing the experiences of three immune checkpoints, including nivolumab, pembrolizumab, and ipilimumab, as well as the pros and cons of using their blockers in relapse control after HSCT. In conclusion, it seems that CI therapy seems effective for this population. Future investigations may provide detailed outlook of this curative options. |
| first_indexed | 2024-03-12T13:33:01Z |
| format | Article |
| id | doaj.art-14007cbe872c4cb79f46f54d5c5786cc |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-04-24T14:00:48Z |
| publishDate | 2022-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-14007cbe872c4cb79f46f54d5c5786cc2024-04-03T12:41:03ZengWileyHealth Science Reports2398-88352022-03-0152n/an/a10.1002/hsr2.536Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitorsElham Roshandel0Farzaneh Tavakoli1Sayeh Parkhideh2Sedigheh Sadat Akhlaghi3Maria Tavakoli Ardakani4Masoud Soleimani5Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran IranHematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran IranHematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran IranDepartment of Internal Medicine, School of Medicine, Ayatollah Taleghani Hospital Shahid Beheshti University of Medical Sciences Tehran IranDepartment of Clinical Pharmacy, School of Pharmacy Shahid Beheshti University of Medical Sciences Tehran IranHematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran IranAbstract Background and Aims Despite the revolutionary effects of hematopoietic stem cell transplantation (HSCT) in treating hematological malignancies, post‐HSCT relapse is considered a critical concern of clinicians. Residual malignant cells employ many mechanisms to evade immune surveillance and survive to cause relapse after transplantation. One of the immune‐frustrating mechanisms through which malignant cells can compromise the antitumor effects is misusing the self‐limiting system of immune response by overexpressing inhibitory molecules to interact with the immune cells, leading them to so‐called “exhausted” and ineffective. Introduction of these molecules, known as immune checkpoints, and blocking them was a prodigious step to decrease the relapses. Methods Using keywords nivolumab, pembrolizumab, and ipilimumab, we investigated the literature to figure out the role of the immune checkpoints in the HSCT setting. Studies in which these agents were administrated for relapse after transplantation were reviewed. Factors such as the interval from the transplant to relapse, previous treatment history, adverse events, and the patients’ outcome were extracted. Results Here we provided a mini‐review discussing the experiences of three immune checkpoints, including nivolumab, pembrolizumab, and ipilimumab, as well as the pros and cons of using their blockers in relapse control after HSCT. In conclusion, it seems that CI therapy seems effective for this population. Future investigations may provide detailed outlook of this curative options.https://doi.org/10.1002/hsr2.536checkpoint blockerhematopoietic stem cell transplantationimmune checkpointrelapse |
| spellingShingle | Elham Roshandel Farzaneh Tavakoli Sayeh Parkhideh Sedigheh Sadat Akhlaghi Maria Tavakoli Ardakani Masoud Soleimani Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors Health Science Reports checkpoint blocker hematopoietic stem cell transplantation immune checkpoint relapse |
| title | Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors |
| title_full | Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors |
| title_fullStr | Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors |
| title_full_unstemmed | Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors |
| title_short | Post‐hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors |
| title_sort | post hematopoietic stem cell transplantation relapse role of checkpoint inhibitors |
| topic | checkpoint blocker hematopoietic stem cell transplantation immune checkpoint relapse |
| url | https://doi.org/10.1002/hsr2.536 |
| work_keys_str_mv | AT elhamroshandel posthematopoieticstemcelltransplantationrelapseroleofcheckpointinhibitors AT farzanehtavakoli posthematopoieticstemcelltransplantationrelapseroleofcheckpointinhibitors AT sayehparkhideh posthematopoieticstemcelltransplantationrelapseroleofcheckpointinhibitors AT sedighehsadatakhlaghi posthematopoieticstemcelltransplantationrelapseroleofcheckpointinhibitors AT mariatavakoliardakani posthematopoieticstemcelltransplantationrelapseroleofcheckpointinhibitors AT masoudsoleimani posthematopoieticstemcelltransplantationrelapseroleofcheckpointinhibitors |